The Senate this week confirmed Scott Gottlieb, President Trump’s nominee to lead the Food and Drug Administration (FDA) opening the door to the approval of the risky Ebola Merck vaccine under new accelerated procedures.
Gottlieb has financial ties to about 20 health companies, including GlaxoSmithKline and Bristol-Myers Squibb, taking $400,000 from drug and medical device companies in consulting and speaking fees between 2013 and 2015.
Gottlieb has pledged to change what he calls FDA’s “cumbersome” drug approval process, and has recommended fast-tracking approval also by using field data while abandoning clinical trials altogether.
The New York Times has said Gottlieb could undo decades of drug safeguards built up to avoid damaging patient’s health.
In fact, Gottlieb is an advocate of uncontrolled and dangerous experimentation with impunity on the USA population in the manner which the Saatchi Bill would have allowed it it had not been stopped by the UK Parliament.
In relation to a potential Ebola epidemic declaration in the USA, Gottlieb’s loose regulatory approach could lead to very dangerous vaccines and ineffective diagnostic kits being issued.